About the special issue
A biosimilar is a biological medicine that has been shown not to have any clinically meaningful differences from the originator medicine in terms of quality, safety, and efficacy. Where regulatory agencies have already recommended the originator biological medicine, the same guidance will normally apply to a biosimilar of that originator. Importantly, the advent of multiple biosimilars of originator drugs provides a major opportunity to reduce cost, which can help to support patient access to biological therapies.
To show our commitment to this important area of research, in 2023, Expert Opinion on Biological Therapy will be publishing its fourth special issue on biosimilars. With contributions from world-class key opinion leaders from across academia and industry, the issue will act as a one-stop shop for all things biosimilars. The Editors are particularly keen to consider studies relating to health economics, bioequivalence and real-world evidence, though commentaries in the form of editorials, reviews and perspective articles are also encouraged.